474 related articles for article (PubMed ID: 32297590)
21. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
[TBL] [Abstract][Full Text] [Related]
22. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
23. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
Okour M; Al-Kofahi M; Austin D
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
[No Abstract] [Full Text] [Related]
24. The race against COVID-19.
Nat Nanotechnol; 2020 Apr; 15(4):239-240. PubMed ID: 32303704
[No Abstract] [Full Text] [Related]
25. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
26. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
Li C; Cheng G
Front Immunol; 2020; 11():1969. PubMed ID: 32849658
[TBL] [Abstract][Full Text] [Related]
27. All together to Fight COVID-19.
Momtazmanesh S; Ochs HD; Uddin LQ; Perc M; Routes JM; Vieira DN; Al-Herz W; Baris S; Prando C; Rosivall L; Abdul Latiff AH; Ulrichs T; Roudenok V; Aldave Becerra JC; Salunke DB; Goudouris E; Condino-Neto A; Stashchak A; Kryvenko O; Stashchak M; Bondarenko A; Rezaei N
Am J Trop Med Hyg; 2020 Jun; 102(6):1181-1183. PubMed ID: 32323644
[TBL] [Abstract][Full Text] [Related]
28. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
Ahn BY; Kang CK; Seo JD; Choe PG; Song SH; Park WB; Park SW; Kim NJ; Oh MD
J Korean Med Sci; 2020 Jun; 35(24):e231. PubMed ID: 32567262
[TBL] [Abstract][Full Text] [Related]
29. Skin manifestations associated with the new coronavirus SARS-CoV-2 disease.
Redondo-Sendino Á; González Sánchez IC; de Victoria Fernández B
Med Clin (Barc); 2020 Nov; 155(9):414-415. PubMed ID: 32873395
[No Abstract] [Full Text] [Related]
30. Some drugs for COVID-19.
Med Lett Drugs Ther; 2020 Apr; 62(1595):49-50. PubMed ID: 32324177
[No Abstract] [Full Text] [Related]
31. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
[TBL] [Abstract][Full Text] [Related]
32. Treatment options for COVID-19: The reality and challenges.
Jean SS; Lee PI; Hsueh PR
J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
[TBL] [Abstract][Full Text] [Related]
33. Does hydroxychloroquine combat COVID-19? A timeline of evidence.
Alia E; Grant-Kels JM
J Am Acad Dermatol; 2020 Jul; 83(1):e33-e34. PubMed ID: 32283236
[No Abstract] [Full Text] [Related]
34. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
[TBL] [Abstract][Full Text] [Related]
35. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
Davido B; Boussaid G; Vaugier I; Lansaman T; Bouchand F; Lawrence C; Alvarez JC; Moine P; Perronne V; Barbot F; Saleh-Mghir A; Perronne C; Annane D; De Truchis P;
Int J Antimicrob Agents; 2020 Oct; 56(4):106129. PubMed ID: 32755653
[TBL] [Abstract][Full Text] [Related]
36. COVID-19: Main therapeutic options.
Hachfi W; Ben Lasfar N
Tunis Med; 2020 Apr; 98(4):299-303. PubMed ID: 32395792
[No Abstract] [Full Text] [Related]
37. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial.
Feeney E; Wallace D; Cotter A; Tinago W; McCarthy C; Keane D; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 May; 21(1):430. PubMed ID: 32450915
[No Abstract] [Full Text] [Related]
38. Clinical features and treatment of COVID-19 patients in northeast Chongqing.
Wan S; Xiang Y; Fang W; Zheng Y; Li B; Hu Y; Lang C; Huang D; Sun Q; Xiong Y; Huang X; Lv J; Luo Y; Shen L; Yang H; Huang G; Yang R
J Med Virol; 2020 Jul; 92(7):797-806. PubMed ID: 32198776
[TBL] [Abstract][Full Text] [Related]
39. Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
Miao H; Li H; Yao Y; Wu M; Lu C; Wang J; Tian M; Li Y; Luo P; Gu J; Yuan B; Wang S; Zhao X; Gan W; Zhao D
Eur J Clin Microbiol Infect Dis; 2020 Dec; 39(12):2211-2223. PubMed ID: 32761481
[TBL] [Abstract][Full Text] [Related]
40. [The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
Gadebusch Bondio M; Marloth M
NTM; 2020 Jun; 28(2):219-225. PubMed ID: 32399903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
